New drug duo aims to tame Graft-Versus-Host disease
NCT ID NCT06388564
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This Phase 2 trial tests whether adding axatilimab to the standard drug ruxolitinib works better for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. About 130 participants aged 12 and older will receive the combination or standard care. The main goal is to see if the combination leads to a complete or partial response within 6 months without needing new therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
A.O.U. Citta Della Salute E Della Scienza Di Torino
Torino, 10126, Italy
-
AZ DELTA
Roeselare, 08800, Belgium
-
Aou Policlinico S. Orsola-Malpighi
Bologna, 40138, Italy
-
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T3N 4N1, Canada
-
Az Sint-Jan Brugge - Oostende Av - Campus Sint-Jan
Bruges, 08000, Belgium
-
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
Bergamo, 24127, Italy
-
Cambridge University Hospitals Nhs Foundation Trust
Cambridge, CB2 0QQ, United Kingdom
-
Centre Hospitalier Universitaire (Chu) de Liege
Liège, 04000, Belgium
-
Chu Sainte-Justine
Montreal, Quebec, H3T 1C5, Canada
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Clatterbridge Cancer Center
Liverpool, L7 8YA, United Kingdom
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico Di Milano Uo Dermatologia
Milan, 20122, Italy
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Fred and Pamela Buffett Cancer Center
Omaha, Nebraska, 68198, United States
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Hospital Clinic Barcelona Main
Barcelona, 08036, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital General Universitario Gregorio Maranon
Madrid, 28007, Spain
-
Hospital Regional Universitario de Malaga
Málaga, 29011, Spain
-
Hospital Universitari I Politecnic La Fe
Valencia, 46026, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, 39008, Spain
-
Hospital Universitario Ramon Y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Virgen Del Rocio
Seville, 41013, Spain
-
Hospital Universitario Virgen de La Arrixaca
El Palmar, 30120, Spain
-
Hospital Universitario Virgen de Las Nieves
Granada, 18014, Spain
-
Ico Institut Catala D Oncologia
Granvia de L'hospitalet 199-203, 08908, Spain
-
Irccs Istituto Clinico Humanitas
Rozzano, 20089, Italy
-
Jessa Ziekenhuis
Hasselt, 03500, Belgium
-
Klinikum Der Johann Wolfgang Goethe University
Frankfurt am Main, 60590, Germany
-
Mayo Clinic Hospital
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ospedale Pediatrico Bambino Gesu Irccs
Rome, 00165, Italy
-
Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore
Rome, 00168, Italy
-
Princess Margaret Cancer Centre - University Health Network
Toronto, Ontario, M5G 2M9, Canada
-
Queen Elizabeth Hospital
Birmingham, B15 2TH, United Kingdom
-
Queen Elizabeth University Hospital
Glasgow, G51 4TF, United Kingdom
-
Smilow Cancer Center-Yale
New Haven, Connecticut, 06510, United States
-
St James University Hospital
Leeds, LS9 7TF, United Kingdom
-
Stanford Cancer Center
Stanford, California, 94305, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
The University of Chicago Medicine
Chicago, Illinois, 60637, United States
-
Universitaetsklinikum Jena
Jena, 07747, Germany
-
Universitaetsklinikum Regensburg
Regensburg, 93053, Germany
-
Universitair Ziekenhuis (Uz) Leuven
Leuven, 03000, Belgium
-
Universitair Ziekenhuis Antwerpen (Uza)
Edegem, 02650, Belgium
-
Universitaire Ziekenhuis Leuven - Gasthuisberg
Leuven, 03000, Belgium
-
Universitatklinikum Freiburg
Freiburg I. Breisgau, 79106, Germany
-
Universitatsklinikum Hamburg Eppendorf
Hamburg, 20251, Germany
-
University Hospital Mannheim
Mannheim, 68167, Germany
-
University Hospital of Wales
Cardiff, CF14 4XW, United Kingdom
-
University of California-Los Angeles Medl Cntr-Oncology Center Bowyer Clinic
Los Angeles, California, 90095, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
University of Maryland-Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
-
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Vancouver General Hospital
Vancouver, V5Z1M9, Canada
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Washington University
St Louis, Missouri, 63110, United States
-
Weill Cornell Medicine
New York, New York, 10021, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axatilimab and ruxolitinib
What this could lead to
If successful, this combination could offer a more effective first-line treatment for chronic graft-versus-host disease, potentially reducing the need for long-term steroids.
What could go wrong
This is an early Phase 2 trial with only 130 participants, so results may not apply to everyone. Side effects from the drug combination are possible, and the study is not yet complete.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.